Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study

Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study

Abstract Background Nearly 50% of breast cancer patients suffer from depression or anxiety. Selective serotonin reuptake inhibitors (SSRIs), the first-line pharmacological treatment for depression, have been implicated in breast cancer development through increased prolactin levels and tamoxifen met...

Full description

Bibliographic Details
Main Authors: John Busby, Ken Mills, Shu-Dong Zhang, Fabio Giuseppe Liberante, Chris R. Cardwell
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Breast Cancer Research
Subjects:
Selective serotonin reuptake inhibitors
Breast cancer
Progression
Survival
Pharmacoepidemiology
Online Access:http://link.springer.com/article/10.1186/s13058-017-0928-0

Internet

http://link.springer.com/article/10.1186/s13058-017-0928-0

Similar Items